Company: CCIXW
Filing Date: 2025-12-05
Form Type: S-4/A
Source: 0001193125-25-309933
Chunk: 532

Company: Churchill Capital Corp IX/Cayman
Filing Date: 2025-12-05
Form: S-4/A
Chunk 532
---
AI (“ PlusAI RSUs ”), issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) will be automatically surrendered and exchanged for (1) the right to receive a number of shares of the Post-Closing Company common stock equal to the Exchange Ratio and (2) the contingent right to receive Earnout Shares that may be issued during the Earnout Period, in each case in accordance with the terms of the Merger Agreement.

<div align='center'>340</div>

Each outstanding and unexercised option to purchase shares of PlusAI common stock (“ PlusAI Option ”) will be assumed by the Post-Closing Company and become an option to purchase shares of the Post-Closing Company common stock containing the same terms, conditions, vesting and other provisions as applied to each such option immediately prior to the Effective Time based on the Exchange Ratio.

Each issued and outstanding PlusAI RSU that is unvested as of immediately prior to the Effective Time will be assumed by the Post-Closing Company and converted into the right to receive restricted stock units subject to shares of the Post-Closing Company common stock, on the same terms, conditions, vesting and other provisions as applied to each such PlusAI RSU immediately prior to the Effective Time based on the Exchange Ratio.

Each issued and outstanding warrant exercisable for PlusAI preferred stock (“ PlusAI Warrant ”) will be exchanged for the right to receive a number of shares of the Post-Closing Company common stock equal to the Exchange Ratio. Each vested and unvested PlusAI warrant will become a warrant to purchase shares of the Post-Closing Company common stock containing the same terms, conditions, vesting, and other provisions as applied to each such warrant immediately prior to the Effective Time based on the Exchange Ratio.

The aggregate consideration to be paid to PlusAI equity holders (“Equity Value”), including PlusAI stockholders and holders of PlusAI SAFEs, vested PlusAI RSUs, vested PlusAI Options, and vested PlusAI warrants, will be calculated as follows:

$1,200,000,000;

adding the amount, if any, of net proceeds raised by PlusAI following the execution of the Merger Agreement but prior to the Closing through the sale (or a series of related sales) of its equity securities in a Permitted Equity Financing; and

subtracting the amount, if any, by which the PlusAI transaction expenses exceed $12.0 million.

Consideration will be paid entirely in shares of the Post-Closing Company common stock in